Related Experiment Videos
Ciglitazone, a new hypoglycemic agent. 5. Effect on renal lesions in C57BL/KsJ-db/db mice
Abstract:
Kidneys of treated and control C57BL/KsJ-db/db mice were analyzed by semiquantitative light microscopy to determine the effects of ciglitazone on the deposition of fluorescein-conjugated IgM and IgG and of PAS-positive material in the glomerular mesangium and renal tubules. Long-term administration (12 and 20 weeks) of ciglitazone significantly improved the blood glucose of most of the treated db/db mice. There appeared to be a reduction of glomerular IgM and IgG in the treated compared with the control group, although IgM did not achieve statistical significance due to heavy stain deposition in two of the treated mice with continuous and severe hyperglycemia. Treated and control mice displayed a similar diffuse expansion and mild thickening of the glomerular mesangium characterized by moderate deposition of PAS-positive material. Expansion of the mesangium was probably not retarded or prevented by ciglitazone therapy since this pathologic process may be controlled by an interaction of metabolic factors other than hyperglycemia per se in the db/db mouse. Glycogen vacuolization (Armeni-Epstein lesion) of the renal tubules was completely ameliorated in the treated mice which showed a reduction of hyperglycemia. The results of this study suggest that prolonged treatment with ciglitazone elicits an improvement of hyperglycemia which seems to retard or reverse glomerular immunopathology and completely reverse tubular derangement but does not prevent expansion of the glomerular matrix in severely diabetic C57BL/KsJ-db/db mice.
Insights
Ciglitazone improved hyperglycemia in diabetic mice, reducing kidney immunopathology and tubular damage. However, it did not prevent glomerular matrix expansion in severe cases.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Diabetic nephropathy is a major complication of diabetes mellitus.
- The C57BL/KsJ-db/db mouse model exhibits key features of human diabetic nephropathy.
- Understanding the renal effects of antidiabetic agents is crucial for managing diabetic kidney disease.
Purpose of the Study:
- To investigate the long-term effects of ciglitazone on kidney pathology in a mouse model of severe diabetes.
- To assess ciglitazone's impact on glomerular immunopathology and mesangial expansion.
- To evaluate ciglitazone's influence on renal tubular changes associated with hyperglycemia.
Main Methods:
- Semiquantitative light microscopy analysis of kidney tissues from treated and control C57BL/KsJ-db/db mice.
- Assessment of fluorescein-conjugated IgM and IgG deposition in glomeruli.
- Evaluation of periodic acid-Schiff (PAS)-positive material in the glomerular mesangium and renal tubules.
Main Results:
- Long-term ciglitazone administration significantly improved blood glucose levels in treated mice.
- A trend towards reduced glomerular IgM and IgG deposition was observed, though not statistically significant for IgM.
- Complete amelioration of glycogen vacuolization (Armeni-Epstein lesion) in renal tubules was noted in treated mice.
- Similar diffuse expansion and mild thickening of the glomerular mesangium with PAS-positive material deposition were seen in both groups.
Conclusions:
- Prolonged ciglitazone treatment improves hyperglycemia, retards/reverses glomerular immunopathology, and completely reverses tubular derangement in diabetic mice.
- Ciglitazone does not prevent glomerular matrix expansion, suggesting other metabolic factors contribute to this process.
- These findings highlight ciglitazone's potential therapeutic benefits for specific kidney complications in diabetes.